Critical appraisal of the accuracy of Acuros-XB and Anisotropic Analytical Algorithm compared to measurement and calculations with the compass system in the delivery of RapidArc clinical plans by unknown
Kathirvel et al. Radiation Oncology 2013, 8:140
http://www.ro-journal.com/content/8/1/140RESEARCH Open AccessCritical appraisal of the accuracy of Acuros-XB
and Anisotropic Analytical Algorithm compared
to measurement and calculations with the
compass system in the delivery of RapidArc
clinical plans
Murugesan Kathirvel1,4, Shanmuga Subramanian1,4, Alessandro Clivio2, Gandhi Arun1,4, Antonella Fogliata2,5*,
Giorgia Nicolini2, Vellaiyan Subramani3, Shanmugam Thirumalai Swamy1,4, Eugenio Vanetti2 and Luca Cozzi2Abstract
Background: The accuracy of the two dose calculation engines available for RapidArc planning (both released for
clinical use) is investigated in comparison to the COMPASS data.
Methods: Two dose calculation algorithms (Acuros-XB and Anisotropic Analytic Algorithm (AAA)) were used to
calculate RA plans and compared to calculations with the Collapsed Cone Convolution algorithm (CC) from the
COMPASS system (IBA Dosimetry). CC calculations, performed on patient data, are based on experimental fluence
measurements with a 2D array of ion chambers mounted on the linac head. The study was conducted on clinical
cases treated with RA. Five cases for each of the following groups were included: Brain, Head and Neck, Thorax,
Pelvis and stereotactic body radiation therapy for hypo-fractionated treatments with small fields. COMPASS
measurements were performed with the iMatrixx-2D array. RapidArc plans were optimized for delivery using 6MV
photons from a Clinac-iX (Varian, Palo Alto, USA).
Accuracy of the RA calculation was appraised by means of: 1) comparison of Dose Volume histograms (DVH)
metrics; 2) analysis of differential dose distributions and determination of mean dose differences per organ; 3) 3D
gamma analysis with distance-to-agreement and dose difference thresholds set to 3%/3 mm or 2%/2 mm for
targets, organs at risks and for the volumes encompassed by the 50 and 10% isodoses.
Results: For almost all parameters, the better agreement was between Acuros-XB and COMPASS independently
from the anatomical site and fractionation. The same result was obtained from the mean dose difference per organ
with Acuros-CC average differences below 0.5% while for AAA-CC data, average deviations exceeded 0.5% and in
the case of the pelvis 1%. Relevance of observed differences determined with the 3D gamma analysis resulted in
a pass rate exceeding 99.5% for Acuros-CC and exceeding 97.5% for AAA-CC.
Conclusions: This study demonstrated that i) a good agreement exists between COMPASS-CC calculations based
on measured fluences with respect to dose distributions obtained with both Acuros-XB and AAA algorithms; ii) 3D
dose distributions reconstructed from actual delivery coincide very precisely with the planned data; iii) a slight
preference in favor of Acuros-XB was observed suggesting the preference for this algorithm in clinical applications.
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Table 1 Brain (Prescription 46.4 Gy [45.0.-50.4])
Parameter Acuros XB AAA CC p
PTV ( Volume [cm3] = 446.4 ± 235.2)
Mean [%] 100.3 ± 0.3 101.8 ± 1.0 100.9 ± 0.7 a,c
D5%- D95% [%] 7.7 ± 1.6 7.6 ± 1.7 7.8 ± 1.7
V95% [%] 95.9 ± 1.3 97.3 ± 2.4 96.3 ± 2.0 c
V105% [%] 0.8 ± 0.6 6.5 ± 3.6 2.5 ± 2.5 a,c
CI90% 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1
Brain Stem ( Volume [cm3] = 24.2 ± 3.9)
D1% [%] 102.7 ± 2.2 104.0 ± 2.1 103.1 ± 2.7 a
D1.8cm3 [%] 94.6 ± 16.7 95.6 ± 17.1 95.2 ± 17.0 a
V50Gy [%] 5.0 ± 11.1 5.7 ± 12.8 5.3 ± 11.9
Chiasm ( Volume [cm3] = 1.1 ± 0.4)
D1% [%] 95.2 ± 16.1 96.6 ± 15.4 95.7 ± 16.7
D1.8cm3 [%] 69.5 ± 31.6 69.3 ± 30.6 68.9 ± 30.7
V50Gy [%] 11.5 ± 25.7 14.4 ± 32.2 15.1 ± 33.8
Lens ( Volume [cm3] = 0.3 ± 0.1)
Mean [%] 8.8 ± 1.9 9.4 ± 2.4 8.8 ± 2.3 c
D1% [%] 10.5 ± 2.3 10.9 ± 2.5 10.3 ± 2.7 c
D1.8cm3 [%] 7.5 ± 1.9 8.1 ± 2.3 7.4 ± 2.1 c
Optic Nerve ( Volume [cm3] = 1.2 ± 0.7)
D1% [%] 77.1 ± 28.6 78.1 ± 28.6 76.6 ± 28.7 a
D1.8cm3 [%] 25.8 ± 11.6 26.6 ± 12.3 26.1 ± 12.2
Retina ( Volume [cm3] = 17.7 ± 1.5)
Mean [%] 19.5 ± 9.7 20.2 ± 9.9 19.7 ± 9.8 a,c
D1% [%] 48.9 ± 21.7 51.3 ± 21.9 50.2 ± 21.2 c
D1.8cm3 [%] 34.6 ± 19.1 35.5 ± 19.5 34.9 ± 18.6 a
a Acuros vs AAA, b Acuros vs CC, c AAA vs CC.
Table 2 HN (Prescription 63.2 Gy [50.0.-70.5])
Parameter Acuros XB AAA CC p
PTV ( Volume [cm3] = 263.4 ± 213.3)
Mean [%] 100.2 ± 0.8 101.1 ± 1.4 100.8 ± 1.0 a,b
D5%- D95% [%] 7.0 ± 2.6 7.1 ± 4.3 6.9 ± 3.6
V95% [%] 96.2 ± 2.0 96.8 ± 3.7 96.7 ± 3.0
V105% [%] 1.1 ± 1.9 4.4 ± 8.3 2.3 ± 4.7
CI95% 1.9 ± 0.8 2.2 ± 1.1 2.0 ± 0.9
Spinal Cord ( Volume [cm3] = 22.9 ± 4.5)
D1% [%] 61.8 ± 3.7 63.7 ± 3.5 62.5 ± 3.3 a,c
D1.8cm3 [%] 60.0 ± 3.7 61.7 ± 3.7 60.5 ± 3.6 a,c
Parotids ( Volume [cm3] = 38.5 ± 19.0)
Mean [%] 48.4 ± 11.6 49.9 ± 11.4 49.0 ± 11.6 a,b,c
D33% [%] 68.0 ± 21.0 69.1 ± 19.7 68.1 ± 20.1 c
D67% [%] 24.6 ± 10.7 26.9 ± 11.7 26.2 ± 11.6 a
Oral Cavity ( Volume [cm3] = 76.1 ± 3.8)
Mean [%] 66.7 ± 13.8 67.4 ± 14.1 67.3 ± 14.1 a
D1% [%] 99.6 ± 1.2 99.0 ± 1.4 99.6 ± 0.9
D33% [%] 76.0 ± 12.1 76.7 ± 12.5 76.5 ± 12.4
Larynx ( Volume [cm3] = 37.1 ± 19.9)
Mean [%] 67.8 ± 3.7 69.0 ± 3.7 69.1 ± 3.7 a,b
D1% [%] 93.1 ± 6.4 94.0 ± 7.5 92.8 ± 7.3 c
D33% [%] 73.6 ± 4.2 74.8 ± 4.3 74.8 ± 4.3 a,b
a Acuros vs AAA, b Acuros vs CC, c AAA vs CC.
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Volumetric Modulated Arc Therapy (VMAT) is, in the
variety of radiation treatment modalities, a possibly valu-
able but also challenging technique because of its intrinsic
complexity involving advanced inverse planning algo-
rithms, dose calculation engines applied to complex fields
and dynamic delivery with several variable parameters
(speed of multileaf collimator, dose rate, gantry rotational
speed). All elements are highly interconnected and con-
tribute together to the generation of dose distributions of
virtually any complexity. As for all advanced treatment
techniques, one fundamental aspect to monitor and to
guarantee is the consistence between planning and deliv-
ery. This to prevent the risk of un-intended mistreatments
with potentially severe implications for patients. The
present study aims to contribute to the determination of
this accuracy in a clinical environment. The VMAT model
investigated here is the RapidArc solution (RA, Varian
Medical Systems, USA) derived from the original proto-
type of Otto [1]. Several studies appraised the subject of
quality assurance of delivery vs calculation of RA [2-13].These used for benchmark of the calculations, experimen-
tal measurements with a plethora of different detectors
and established consolidated practice in the clinical rou-
tine. As a general summary, all these studies suggested the
safe and reliable consistency of calculations vs delivery ei-
ther in simple geometrical or anthropomorphic phantoms.
Some studies [14,15] addressed the usage of Monte Carlo
methods to convert delivery information registered by the
linacs during irradiation in input data for some sort of ”ac-
tual” in-patient dose calculation to compare to planned
dose distributions. Limit of this branch of investigations is
the need of computational tools not commercially avail-
able and not easily implementable in routine settings. On
the same line, little has been done so far, to use measured
data to recalculate the ‘actual’ dose in the patients. Investi-
gations based on the usage of electronic portal imaging
devices, used to measure transmitted dose through the pa-
tients represents the current cutting edge of the research.
Pioneering studies demonstrated the possibility to recon-
struct reliable dose in a quasi in-vivo setting by using as
patient model the Cone Beam CT data that can be ac-
quired daily before treatment [16]. From a different per-
spective, it is possible also to use measurement devices to
detect the fluence generated by the delivery process before
entering the patient and from this, to determine the
”actual” delivered dose inside a patient model. The
Table 3 Thorax (Prescription 46.2 Gy [39.6.-50.0])
Parameter Acuros XB AAA CC p
PTV ( Volume [cm3] = 516.8 ± 398.3)
Mean [%] 100.3 ± 1.0 101.2 ± 0.4 100.9 ± 1.2
D5%- D95% [%] 10.3 ± 1.6 9.8 ± 3.0 10.8 ± 2.6 c
V95% [%] 94.3 ± 2.2 95.3 ± 2.4 94.4 ± 3.3 a
V105% [%] 4.1 ± 2.4 6.8 ± 5.7 7.0 ± 5.1
CI90% 1.8 ± 1.2 1.9 ± 1.2 2.0 ± 1.1
Ipsil Lung ( Volume [cm3] = 1700.2 ± 318.3)
Mean [%] 43.3 ± 24.7 43.3 ± 24.7 42.6 ± 24.5
V20Gy [%] 48.0 ± 25.7 47.8 ± 25.7 47.5 ± 25.7 b
D1% [%] 104.3 ± 0.9 103.9 ± 0.9 104.5 ± 0.2 a
Contr Lung ( Volume [cm3] = 2048.4 ± 42.1)
Mean [%] 9.6 ± 2.6 9.8 ± 2.8 9.1 ± 2.3
V20Gy [%] 3.2 ± 2.6 3.2 ± 2.6 3.0 ± 2.4
D1% [%] 58.2 ± 19.3 58.8 ± 19.9 57.1 ± 18.2
Lungs ( Volume [cm3] = 3382.7 ± 479.6)
Mean [%] 24.5 ± 7.0 24.9 ± 7.2 23.9 ± 6.9 b,c
V20Gy [%] 19.8 ± 7.7 19.9 ± 7.7 19.4 ± 7.7 b,c
D1% [%] 98.4 ± 4.5 98.4 ± 4.3 98.2 ± 4.6
Heart ( Volume [cm3] = 501.3 ± 31.4)
Mean [%] 39.7 ± 27.0 40.4 ± 27.6 39.7 ± 27.3 c
D1% [%] 101.9 ± 3.0 103.5 ± 3.0 102.2 ± 3.9 a
Spinal Canal ( Volume [cm3] = 31.9 ± 3.3)
D1% [%] 67.6 ± 23.3 68.5 ± 23.5 67.9 ± 23.1 a
D1.8cm3 [%] 63.7 ± 23.4 64.5 ± 23.5 64.1 ± 23.5 b
a Acuros vs AAA, b Acuros vs CC, c AAA vs CC.
Table 4 Pelvis (Prescription 51.6 Gy [45.0.-56.0])
Parameter Acuros XB AAA CC p
PTV ( Volume [cm3] = 817.6 ± 527.5)
Mean [%] 98.5 ± 3.3 100.3 ± 3.3 98.9 ± 3.2 a,c
D5%- D95% [%] 6.8 ± 0.9 6.3 ± 1.0 6.7 ± 1.2 a,c
V95% [%] 80.3 ± 35.1 88.9 ± 22.2 82.5 ± 28.7
V105% [%] 1.1 ± 1.6 4.4 ± 5.6 1.8 ± 3.8
CI90% 1.2 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 a,c
Bladder ( Volume [cm3] = 259.3 ± 114.6)
Mean [%] 70.4 ± 16.4 72.2 ± 16.8 70.6 ± 16.5 a,c
D1% [%] 101.6 ± 2.5 103.6 ± 2.8 102.1 ± 2.8 a,c
D67% [%] 55.3 ± 29.0 56.7 ± 29.7 55.2 ± 29.1 a,c
Rectum ( Volume [cm3] = 101.6 ± 44.8)
Mean [%] 68.4 ± 17.3 70.0 ± 17.5 68.3 ± 16.9 a,c
D1% [%] 100.4 ± 4.2 101.9 ± 4.0 100.6 ± 4.1 a,c
D67% [%] 53.4 ± 28.1 55.0 ± 28.5 53.3 ± 27.9 a,c
Femurs ( Volume [cm3] = 172.7 ± 46.3)
Mean [%] 38.9 ± 6.8 40.0 ± 7.0 38.7 ± 7.0 a,c
D1% [%] 75.8 ± 17.9 77.9 ± 18.5 76.0 ± 17.9 a,c
D1.8cm3 [%] 75.7 ± 18.0 77.8 ± 18.6 75.9 ± 18.0 a,c
Bowel ( Volume [cm3] = 1062.2 ± 903.1)
Mean [%] 28.0 ± 19.4 28.8 ± 19.6 27.3 ± 19.2 a,b,c
D1% [%] 68.8 ± 45.9 69.9 ± 46.3 68.5 ± 45.9 a,c
D1.8cm3 [%] 69.0 ± 48.1 69.9 ± 48.4 68.5 ± 48.0 a,b,c
a Acuros vs AAA, b Acuros vs CC, c AAA vs CC.
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mercial system which allows to investigate this area. In fact,
the COMPASS consists of an experimental device, the
Matrix 2D array of ionization chambers which, mounted
on the linac head, can measure the output fluence of any
given field. This measured fluence can be used as input to a
calculation engine based on a Collapsed Cone algorithm
(CC) which allows to compute a 3D dose distribution in a
phantom or in a patient CT dataset. In this way, although
depending on the CC algorithm and the CT set used, it is
possible to generate a kind of ‘’delivered” dose distribution.
The COMPASS system has been studied in terms of its in-
trinsic accuracy compared to other measurement devices as
well as in terms of its clinical usability [17-21] for IMRT
techniques. In this study, COMPASS usage will be ex-
tended to VMAT 3D quality assurance.
Aim of the study is the investigation of the accuracy of
the two dose calculation engines available for RA plan-
ning (the Acuros-XB and the Anisotropic Analytical Al-
gorithm both released for clinical use) in comparison to
the COMPASS data for a number of cases representing
a wide spectrum of possible clinical conditions.Methods
Patients’ selection
The study was designed to explore a wide range of clinical
applications of RapidArc. For this reason five localisations
were identified and for each of them, five patients were se-
lected from the clinical database. Localisations (or groups)
were: brain, head and neck (HN), thorax, pelvis; these
represented conventional fractionation regimens and
fields of medium to large size. A fifth group was defined
including patients treated for stereotactic body radio-
therapy (SBRT) with hypofractionated regimen and usage
of small fields to define the arcs. To increase the variability
of the cases, patients with different dose prescriptions
were included in the study and, to make them comparable,
analysis has been performed in terms of percentage doses.
Tables 1, 2, 3, 4 and 5 report also the mean prescribed
doses and ranges for each of the five groups. For all pa-
tients, the planning CT and structures were shared in
DICOM format between the planning system and the ex-
perimental COMPASS system described below. For each
patient the planning target volume (PTV) and several or-
gans at risk were considered. These depend upon the
localization and included: brain stem, chiasm, lenses, optic
nerves, retina, spinal cord, parotids, oral cavity, larynx,
Table 5 SBRT (Prescription 60.0 Gy [60.0.-60.0])
Parameter Acuros XB AAA CC p
PTV ( Volume [cm3] = 68.9 ± 50.2)
Mean [%] 102.2 ± 2.4 102.9 ± 3.4 102.0 ± 2.7
D5%- D95% [%] 19.2 ± 4.0 18.1 ± 2.5 20.2 ± 3.6 b
V95% [%] 91.9 ± 3.0 93.2 ± 4.0 91.0 ± 3.1 b,c
V105% [%] 35.0 ± 16.9 41.2 ± 21.4 35.2 ± 17.0
CI90% 1.1 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 b,c
Ipsil Lung ( Volume [cm3] = 1202.5 ± 421.1)
Mean [%] 14.7 ± 12.7 14.8 ± 12.6 14.8 ± 12.5
V20Gy [%] 15.1 ± 17.4 15.0 ± 17.3 15.3 ± 17.1
D1% [%] 74.8 ± 43.5 75.2 ± 43.8 74.9 ± 43.7
Contr Lung ( Volume [cm3] = 1164.7 ± 601.0)
Mean [%] 2.4 ± 2.0 2.4 ± 2.0 2.2 ± 1.9
V5Gy [%] 5.4 ± 10.5 5.1 ± 9.9 4.9 ± 9.4
D1% [%] 7.9 ± 4.9 8.0 ± 4.9 7.7 ± 5.0 b,c
Ribs ( Volume [cm3] = 213.5 ± 327.2)
D1% [%] 83.3 ± 15.0 85.1 ± 15.7 83.7 ± 14.7 a
V30Gy [%] 19.0 ± 18.7 20.1 ± 19.9 19.1 ± 18.8
Liver ( Volume [cm3] = 1135.0 ± 489.9)
Mean [%] 14.7 ± 4.3 15.0 ± 4.3 14.5 ± 4.3 a,b,c
D1% [%] 88.6 ± 33.1 90.1 ± 33.8 89.0 ± 33.3
V21Gy [%] 11.6 ± 6.2 11.8 ± 6.2 11.6 ± 6.1
a Acuros vs AAA, b Acuros vs CC, c AAA vs CC.
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bladder, bowels, femoral heads. Tables 1, 2, 3, 4 and 5
report the volumes of each of these targets and organs
at risk.
Dose calculation algorithms and experimental
instrumentation
RapidArc plans were optimized using the Progressive
Resolution Optimiser algorithm (PRO 10.0.28) [22] imple-
mented in the Eclipse planning system (Varian Medical
Systems, USA) and dose calculations were performed
using for each case both the Anisotropic Analytical Algo-
rithm (AAA) [23] and the Acuros-XB algorithm [24] (ver-
sion 10.0.28 for both) using a spatial resolution of 2.5 mm
in the x and y directions. All plans were optimized and
calculated for 6MV photon beams generated by a Clinac
iX equipped with a Millennium 120 Multileaf Collimator.
Given the variability of the clinical cases, RA plans in-
cluded full, partial, single and multiple arcs to cover the
spectrum of routine application of the treatment
technique.
The COMPASS system (IBA Dosimetry, Germany), in
its version 2.0.7, was used to generate independent data
for the verification of the accuracy of the two Eclipse al-
gorithms with respect to actual delivery. For a detailed
description of the COMPASS system, readers arereferred to the original publications [17,18]. Its principle
can be summarized as follows. A detector is mounted on
the linac gantry (typically at the accessory mount holder)
and it is used to measure the fluence produced by the
linac for a given field (static or dynamic, modulated or
plain). The measured fluence is used then as input data
for a 3D convolution algorithm (Collapsed Cone) which
allows to reconstruct the dose ‘’delivered” by the linac in
a CT dataset (which could be a phantom or a patient
set, even a Cone Beam CT). In the present case, the
same CT sets were used for RA planning and for COM-
PASS calculations. The dose calculation was performed
with a resolution of 2.5 mm. The detector used for flu-
ence measurements is the Matrixx 2D array of ion
chambers with a spatial resolution of 7.6 mm (center-to-
center distance of the chambers). Fine interpolation of
data to build an high resolution fluence is part of the
COMPASS algorithm itself. In this study, the entire
COMPASS system can be considered as a pre-treatment
quality assurance tool (since it was used in absence of
the patient) and it was used to benchmark the accuracy
of the Eclipse calculations vs. recalculation from actual
fluence delivery. In the present study no assessment of
the intrinsic accuracy of CC is provided and readers are
referred to Korrevaar et al [17] for an appraisal.
Analysis and evaluation tools
To appraise the accuracy of the algorithms from Eclipse
with respect of the calculations of COMPASS, three
levels of tests were designed.
The first level of investigation was based on the con-
ventional analysis of parameters derived from Dose Vol-
ume Histograms (DVH). To avoid possible biases in the
construction of DVHs, the 3D dose matrices from
COMPASS were imported in Eclipse so that only one
engine was applied to build them. The analysis included
for target volumes (PTV) the mean dose, the coverage
expressed as the volume receiving 95% or 105% of the
prescription dose (V95% and V105%), the homogeneity
expressed as the difference between the dose to 5% and
to 95% of it (D5%-D95%) and the conformality expressed
as the ratio between the volume of the 95% isodose and
the PTV (conformity index, CI95%). For organs at risk,
various parameters were quantified depending on the
specificity of each of them in the spirit of ICRU 83 rec-
ommendations [25]. These included: mean doses, max-
imum significant doses (e.g. D1% or D1.8cm3), doses to a
given volume (Dx%) and volumes receiving given dose
levels (Vx%).
The second level of investigation was aiming to quan-
tify global differences in the dose distributions between
the different algorithms and conditions. This was better
expressed in terms of mean dose difference for each
PTV or organ at risk (depending on the groups) for the
Figure 1 Graphical summary of the average percentage dose difference between the various algorithms for various significant
volumes or organs. Data, obtained from 3D dose distributions, are presented separately for the five groups: brain, head and neck, thorax, pelvis
and SBRT clinical cases.
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Positive differences indicated a dose over-estimation of
the first algorithm with respect to the second, and vice-
versa. Objective was to identify and quantify possible
systematic trends.
The third level of analysis was aiming to determine
the possible relevance of observed discrepancies. The
adopted tool was the 3D gamma analysis based on a
generalization of the gamma of Low concept [26]. The
computational methods here adopted has been described
in Fogliata et al. [27]. The 3D gamma test was applied to
each of the volumes listed above representing theclinically relevant objects. To appraise also the accuracy
in the low dose range, the test was applied also to the
volume of patients encompassed by the 50% and 10%
isodoses. All tests were repeated using two sets of
thresholds: a conventional dose difference and distance
to agreement (DTA) of 3%/3 mm, used in routine clin-
ical practice for quality assurance purposes, and a more
restrictive 2%/2 mm aiming to stress the algorithms at
the limit of their calculation resolution. Results were
expressed in terms of pass rates, i.e. the percentage of
voxels in a volume passing the gamma test. As a general
concept, in the comparison between AAA (or Acuros)
Figure 2 Graphical summary of the failure rate after 3D gamma analysis (with thresholds set to 3%/3 mm (a) or to 2%/2 mm (b)). Data,
presented for various significant volumes or organs at risk, are presented separately for the five groups: head and neck, thorax, pelvis and SBRT
clinical cases.
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Table 6 Gamma agreement index
Group AAA_Acuros CC_Acuros CC_AAA p
GAI [%] with criteria 3 %/3 mm
Brain 99.1 ± 2.1 99.2 ± 2.1 99.7 ± 0.6 b
H&N 99.0 ± 1.4 99.4 ± 0.9 99.4 ± 1.0 a,b
Thorax 99.6 ± 0.8 99.9 ± 0.2 99.7 ± 0.33 -
Pelvis 99.4 ± 1.4 99.9 ± 0.3 98.9 ± 3.1 a,c
SBRT 99.6 ± 1.4 100.0 ± 0.0 99.5 ± 2.1 -
GAI [%] with criteria 2 %/2 mm
Brain 97.0 ± 4.5 98.0 ± 3.6 98.7 ± 3.4 a,b
H&N 91.1 ± 7.3 96.9 ± 3.2 96.2 ± 5.5 a,b
Thorax 96.4 ± 5.7 99.2 ± 1.3 97.9 ± 2.4 a,c
Pelvis 92.2 ± 11.3 98.8 ± 2.3 91.9 ± 14.4 a,c
SBRT 97.8 ± 4.8 99.9 ± 0.2 98.5 ± 4.9 a
a AAA_Acuros vs CC_ Acuros, b AAA_ Acuros vs CC_AAA, c CC_ Acuros
vs CC_AAA.
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risk of relevant discrepancies between the dose delivered
to a patient and the intended plan, outside the ‘’recov-
ery” tolerances of the gamma measure. In the absence of
any consensus on acceptability levels, it is assumed here
that any pass rate higher than 97% corresponds to com-
pletely satisfactory agreement while, conversely, pass
rates inferior to 90% would recommend some care
suggesting possible clinical risks.
For all comparisons, statistical significance at 5% was
assessed by means of Fisher’s signed test.
Results
Tables 1, 2, 3, 4 and 5 present a summary of the quanti-
tative comparison of DVH obtained from the dose distri-
butions computed with Acuros-XB and AAA and from
the CC based calculations on the experimental COM-
PASS. Data are presented separately for the four groups
showing for each parameter the mean over the patients
in the group and the standard deviation; in the p column
are identified the cases where significant differences
were observed. For each organ at risk or target volume it
is reported also the mean volume and its standard devi-
ation. All data are reported in % because of the different
dose prescriptions. Although sometimes statistically sig-
nificant, no macroscopic discrepancies were observed
between all algorithm for all parameters.
Figure 1 contains the graphical summary of the a-
verage percentage dose difference between the three al-
gorithms for the target volumes and organs at risk for
the five groups. Data, obtained from 3D dose distribu-
tions of the plan differences, are presented separately for
the five groups. The error bars represent one standard
deviation. As a general trend, AAA over-estimate the
dose compared to Acuros and to CC. Acuros and CCare on average in better agreement with a more variable
pattern of over- and under- estimation of the doses. The
average overestimation of AAA respect to Acuros for
the analyzed organs is 0.70 ± 0.69% and of AAA respect
to COMPASS-CC is 0.88 ± 0.46%. The average difference
between Acuros and COMPASS-CC is −0.02 ± 0.51%. In
all cases for brain, head and neck, thorax and SBRT,
average differences did not exceeded 1.3%, for pelvis
these reached 1.8%. In most of the cases the observed
differences resulted statistically significant with the ex-
ception of the chiasm in the brain, the larynx in head
and neck, the lungs in the thorax and the PTV and liver
in SBRT, where no significance was determined.
Figure 2 is the graphical summary of the 3D gamma
analysis. Results are shown in terms of the residual fail-
ure rate expressed as percentage of voxels in the vol-
umes under analysis not passing the gamma test with
thresholds set to 3%/3 mm (a) or to 2%/2 mm (b). As
for the previous results, data are presented for the five
groups separately and for the same volumes of interest.
The average pass rates (expressed as Gamma Agreement
Index, i.e. the percentage of voxels in the organ passing
the 3D gamma test) are summarized in Table 6. In gen-
eral, with the conventional thresholds of 3%/3 mm, all
algorithms did agree with a maximum failure of ~3%
(larynx and rectum). With the tighter thresholds, Acuros
and COMPASS-CC remained highly consistent with
average failure rate inferior to ~3% with only one excep-
tion for the low isodose and larynx case in the head and
neck (~6% and ~4% respectively). High failure rates were
observed for AAA compared to Acuros or COMPASS-
CC, particularly for PTVs. A general better agreement
between AAA and COMPASS-CC was observed than
between AAA and Acuros.
Discussion and conclusion
The aim of the present study was the assessment of the
degree of agreement between 3D dose distributions
calculated for clinical RA plans against independent
calculations based on actual fluence delivered by the lin-
ear accelerators, before entering in the patient. These
fluences were used to calculate the dose ‘delivered’ to
the patients using the planning CT dataset. In this way,
the object of the study is in practice the appraisal of the
accuracy of the planning calculation engines in simu-
lating the real delivery by the linear accelerator. In fact,
errors and issues attributable to changes in patient pos-
ition, anatomy and shape are not accounted for because
all calculations were performed on the same planning
CT, a single snapshot in time. The study as presented
here, cannot provide an absolute determination of the
accuracy of the clinical algorithms because, in the ex-
perimental arm, another algorithm (CC) is used by the
COMPASS system. This kind of loop is unavoidable
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in the EPID based [16] methods) because whatever the
strategy, it is always necessary to convert some kind of
measurement into a 3D dose distribution inside the pa-
tient. Validation of the CC algorithm was not subject of
this study and was addressed by its developers in their
founding studies. Here CC accuracy was considered to
be adequate for quality assurance purpose as determined
by Korevaar [17] or Nakaguchi [19] and comparable to
what achievable with films or other dosimetry devices
(Mapcheck). Within the frame of validity defined above,
the two algorithms available for clinical calculation of
RA plans, Acuros-XB and AAA were compared against
benchmark data from COMPASS for a total of 25 pa-
tients, divided in 5 groups representing different treat-
ment sites, dose prescription and plan complexity. From
the three different analyses performed on the data it is
possible to extract some general consideration. Based on
DVH analysis, both Acuros-XB and AAA resulted in good
agreement with COMPASS-CC calculations. Acuros-XB
showed smaller differences than AAA for basically all pa-
rameters usually used for plan evaluation and for dose
reporting as recommended by ICRU [25]. This fact is re-
assuring because it suggests that, for RA, the calculation
engines, with all their inherent approximations, are any-
way adequate to model the real delivery within acceptable
levels. In fact the differences reported in Tables 1, 2, 3, 4
and 5 would not be considered clinically alarming and
could be well ascribed to the intrinsic variation between
different algorithms. In this respect it is important to no-
tice that for most of the patients, the anatomical sites
studied included highly heterogeneous tissues which are
differently managed and modeled by the different algo-
rithms as demonstrated in earlier studies [28-30]. The
same results suggest also that even if 3D dose reconstruc-
tion in patients are available as part of advanced quality
assurance procedures, an analysis based only on DVH pa-
rameters could be insufficient to determine possibly clin-
ical relevant features. More interesting results were in fact
obtained from the inspection of 3D dose differences per
organ. In this case, it was possible to demonstrate the sys-
tematic difference between Acuros-XB and AAA with re-
spect to COMPASS-CC and the smaller discrepancies
when Acuros-XB is used. In addition, it was possible to
demonstrate that calculations based on AAA have a sys-
tematic trend of over-estimation of the dose actually deliv-
ered to the patients. Although the absolute values are
small (below 2%), this could have some clinical impact
(e.g. with AAA more plans might be considered not ac-
ceptable then Acuros-XB due to dosimetric constraints vi-
olations). Finally, the application of more complex tools
like the 3D gamma, allowed to determine that Acuros-XB
is more robust and accurate than AAA with also tight
thresholds (2%/2 mm). The clinical relevance of this relieson the fact that, in the absence of any perturbation due to
patient positioning or organs motion, Acuros-XB repro-
duces almost perfectly the delivery suggesting its lower
sensitivity to the two above elements if compared to AAA.
In conclusion, this study demonstrated that i) a good
agreement exists between COMPASS-CC calculations
based on measured fluences with respect to dose distri-
butions obtained with both Acuros-XB and AAA algo-
rithms; ii) 3D dose distributions reconstructed from
actual delivery coincide very precisely with the planned
data; iii) a slight preference in favor of Acuros-XB was
observed suggesting the preference for this algorithm in
clinical applications.
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